What is NSC Lung Cancer Phase 3 MPDL 3280A OAK Study?

Category: Others

false

The Oak Study is a phase III randomized study, to investigate the efficacy and safety of MPDL3280A (ANTI-PD-L1 ANTIBODY) compared with docetaxel in patients with non-small cell lung cancer after failure with platinum containing chemotherapy.

No patients have reported taking NSC Lung Cancer Phase 3 MPDL 3280A OAK Study.
Last updated:
There are no evaluations for NSC Lung Cancer Phase 3 MPDL 3280A OAK Study.